A possible new treatment for elevated Lp(a) in CVD - HORIZON

• Research type

  Research Study

• Full title

  A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease (CVD).

• IRAS ID

  267092

• Contact name

  Azfar Zaman

• Contact email

  azfar.zaman@nhs.net

• Sponsor organisation

  Novartis Pharma AG

• Eudract number

  2019-001076-11

• Clinicaltrials.gov Identifier

  NCT04023552

• Duration of Study in the UK

  3 years, 7 months, 3 days

• Research summary

  Lipoprotein (a) is recognised as an independent risk factor biomarker for Cardiovascular Disease. This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a). The study population will consist of subjects with established CVD; 7,680 males and females; age 18 to 80 years both inclusive.

• REC name

  North West - Greater Manchester South Research Ethics Committee

• REC reference

  20/NW/0310

• Date of REC Opinion

  17 Sep 2020

• REC opinion

  Further Information Favourable Opinion